Recombinant Human Erythropoietin Dose, Serum Adiponectin, and All-Cause Mortality in Patients Beginning Hemodialysis

NCT00457561 · Status: COMPLETED · Type: OBSERVATIONAL

Last updated 2007-04-06

No results posted yet for this study

Summary

Decreased body fat mass, possibly mediated through the effects of elevated serum adiponectin levels, may be associated with requirements for higher recombinant human erythropoietin doses and a subsequent worse prognosis in patients beginning hemodialysis.

Conditions

  • Hemodialysis

Sponsors & Collaborators

  • Hamamatsu University

    lead OTHER

Principal Investigators

  • Naro Ohashi, MD,PhD · First Department of Medicine, Hamamatsu University School of Medicine

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00457561 on ClinicalTrials.gov